PCSK9 and metabolic dysfunction-associated steatotic liver disease: Hence, these liver‐specific genes, including PKLR, PNPLA3, and PCSK9, may potentially be targeted for the treatment of HCC, and PKLR may potentially be targeted for the treatment of NAFLD.